Unmasking Racial Disparity in the Diagnosis and Treatment of Hidradenitis Suppurativa

• Published in: Curēus (Palo Alto, CA) Vol. 15; no. 6; p. e41190
• Main Authors: Anthony, Michelle R, Abdi, Parsa, Farkouh, Christopher, Maibach, Howard I
• Format: Journal Article
• Language: English
• Published: United States Cureus Inc 30.06.2023; Cureus
• Subjects: Clinical trials; Dermatology; Education; Health care access; Hispanic Americans; Inequality; Medical diagnosis; Minority & ethnic groups; Outreach services; Public Health; Racial differences; United States > US; San Francisco California; racial disparities; hidradenitis suppurativa; black americans; diagnosis delay; minority representation
• ISSN: 2168-8184; 2168-8184
• DOI: 10.7759/cureus.41190

Hidradenitis suppurativa (HS) is a chronic, profoundly incapacitating disease predominantly affecting the apocrine gland-rich areas of the human body. Although it affects 0.05% to 4% of the general population, there exists a significant racial disparity, with people of color, particularly Black individuals, experiencing a notably higher prevalence. Despite this disparity, the current literature lacks comprehensive analyses of HS concerning race and ethnicity, revealing a systemic blind spot in understanding and addressing the disease's racially disproportionate impacts. In this commentary, we aim to shed light on these racial disparities, focusing specifically on the stark inequities related to the timely diagnosis and subsequent dermatological care of HS in the United States. This commentary explores the racial bias in HS prevalence, severity, diagnostic delay, access to specialized care, and underrepresentation in clinical trials. By emphasizing the urgent need to address these disparities, we seek to foster an inclusive dialogue and drive proactive efforts toward achieving equitable care and research representation for all populations affected by this debilitating condition. Through this discussion, we aim to pave the way for a healthcare landscape that acknowledges and addresses the racial disparities inherent in HS, ensuring that advancements in the management of the disease cater to the needs of all populations, irrespective of their racial or ethnic background.